David Woodhouse, NGM CEO

NGM con­cedes key fail­ure for their lead NASH drug, clos­ing the door on a piv­otal fol­lowup — and ask­ing an­a­lysts to look past the wreck­age in­to the pipeline

A lit­tle more than a year ago NGM whipped up con­sid­er­able en­thu­si­asm for its an­ti-fi­brot­ic NASH drug aldafer­min based on a co­hort of pa­tients who …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.